Changes in routine mouse home-cage behavioral activities have been used recently to study alterations of neural circuits caused by genetic and environmental modifications and by drug administration. Nevertheless, automatic assessment of mouse home-cage behaviors remains challenging due to the cost of proprietary systems and to the difficulty in adjusting systems to different monitoring conditions. Here we present software for the automatic quantification of multiple facets of mouse home-cage behaviors, suitable for continuous 24 h video monitoring. We used this program to assess behavioral changes in male and female R6/2 transgenic mouse models of Huntington's disease over a 10-week period. Consistent with the well-known progressive motor coordination deficits of R6/2 mice, their hanging, rearing, and climbing activity declined as the disease progressed. R6/2 mice also exhibited frequent disturbances in their resting activity compared to wild-type mice, suggesting that R6/2 mice are more restless and wakeful. Behavioral differences were seen earlier for male R6/2 mice than female R6/2 mice, and "behavioral signatures" based on multiple behaviors enabled us to distinguish male R6/2 mice from sex- and age-matched wild-type controls as early as 5 weeks of age. These results demonstrate that the automated behavioral classification software that we developed ("OpenCage") provides a powerful tool for analyzing natural home-cage mouse behaviors, and for constructing behavioral signatures that will be useful for assessing therapeutic strategies. The OpenCage software is available under an open-source GNU General Public License, allowing other users to freely modify and extend it to suit their purposes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2012.01.015DOI Listing

Publication Analysis

Top Keywords

r6/2 mice
24
mouse home-cage
12
home-cage behavioral
8
male female
8
mouse models
8
models huntington's
8
huntington's disease
8
home-cage behaviors
8
female r6/2
8
male r6/2
8

Similar Publications

Pleiotropic effects of mutant huntingtin on retinopathy in two mouse models of Huntington's disease.

Neurobiol Dis

December 2024

Department of Physiology & Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:

Huntington's disease (HD) is caused by the expansion of a CAG repeat, encoding a string of glutamines (polyQ) in the first exon of the huntingtin gene (HTTex1). This mutant huntingtin protein (mHTT) with extended polyQ forms aggregates in cortical and striatal neurons, causing cell damage and death. The retina is part of the central nervous system (CNS), and visual deficits and structural abnormalities in the retina of HD patients have been observed.

View Article and Find Full Text PDF

There is a growing consensus that brain development in Huntington's disease (HD) is abnormal, leading to the idea that HD is not only a neurodegenerative but also a neurodevelopmental disorder. Indeed, structural and functional abnormalities have been observed during brain development in both humans and animal models of HD. However, a concurrent study of cortical and striatal development in a genetic model of HD is still lacking.

View Article and Find Full Text PDF
Article Synopsis
  • - Huntington's disease (HD) is a genetic neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene, leading to the accumulation of harmful mutant proteins in nerve cells.
  • - The NLRP3 inflammasome plays a crucial role in inflammation and its overactivation contributes to neurodegeneration in HD; inhibiting it showed potential benefits in mice by reducing toxic inflammation and neuronal damage.
  • - Antcin-H, a compound derived from the medicinal fungus Antrodia cinnamomea, was found to decrease neuroinflammation and toxicity while improving motor function and survival rates in a mouse model of HD, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF

Huntington's disease (HD) is a progressive neurodegenerative disorder with no cure, characterized by significant neurodegeneration of striatal GABAergic medium spiny neurons (MSNs). Early stages of the disease are characterized by the loss of dopamine 2 receptor-expressing MSNs (D2 MSNs) followed by degeneration of dopamine 1 receptor-expressing MSNs (D1 MSNs), leading to aberrant basal ganglia signaling. While the early degeneration of D2 MSNs and impaired GABAergic transmission are well-documented, potassium chloride cotransporter 2 (KCC2), a key regulator of intracellular chloride (Cl), and therefore GABAergic signaling, has not been characterized in D1 and D2 MSNs in HD.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research indicates that blocking the interaction between valosin-containing protein (VCP) and mutant huntingtin (mtHtt) can help prevent mitochondrial damage in Huntington's disease models.
  • A newly developed protein-like polymer (PLP) has shown effectiveness in cellular and animal models, significantly inhibiting mitochondrial destruction and proving more stable than control oligopeptides.
  • PLP has a remarkably longer circulation half-life (152 hours) and outperforms free peptide in efficacy tests, suggesting it could be a promising platform for developing treatments for central nervous system disorders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!